GSK demerger set for mid-2022

Thursday 24 June 2021

United Kingdom

The demerger of GlaxoSmithKline Plc into separate consumer healthcare and biopharmaceutical companies will result in a reset of R&D priorities, a compound annual growth rate in sales of more than 5% over the next five years and a new dividend policy, Emma Walmsley announced. The widely anticipated demerger will take effect in mid-2022 creating a new publically listed consumer healthcare company and a biopharma group focused on vaccines and speciality medicines. The consumer healthcare business is currently 68% owned by GSK and 32% by Pfizer Inc.